Bayer’s SMART-Finder Study: A Closer Look at T2DM and Kidney Health

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting a study titled ‘SMART-Finder – Identification of Patients With Elevated UACR Levels in a T2DM Cohort.’ The study aims to identify individuals with type 2 diabetes mellitus (T2DM) who exhibit increased levels of albumin in their urine, a potential indicator of kidney damage. This research is significant as it seeks to understand the prevalence and progression of kidney-related complications in T2DM patients using the myTherapy app in Germany.

Intervention/Treatment: The study involves observational data collection from T2DM patients using the myTherapy app. Participants are already receiving standard T2DM treatments, including drugs like Finerenone (Kerendia) and other T2DM medications, as prescribed by their physicians.

Study Design: This is an observational cohort study focusing on real-world data. It does not involve any specific interventions or masking. The primary purpose is to observe and analyze changes in urine-albumin-creatinine-ratio (UACR) levels over time among the participants.

Study Timeline: The study began on August 18, 2023, with data collection running from October 2022 to December 2024. The primary completion is expected within this period, with the last update submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data analysis.

Market Implications: The study’s findings could impact Bayer AG’s stock performance by highlighting the effectiveness of their T2DM treatments in managing kidney-related complications. Positive outcomes might boost investor confidence and position Bayer favorably against competitors in the diabetes care market. The study’s focus on real-world data could also enhance Bayer’s reputation for innovative research approaches.

The study is ongoing, with further details available on the ClinicalTrials portal.